Gritstone bio (GRTS) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart Transcripts

GRTS Stock Forecast

Gritstone bio stock forecast is as follows: an average price target of $4.67 (represents a 18505.58% upside from GRTS’s last price of $0.03) and a rating consensus of 'Buy', based on 5 wall street analysts offering a 1-year stock forecast.

GRTS Price Target

The average price target for Gritstone bio (GRTS) is $4.67 based on 1-year price targets from 5 Wall Street analysts in the past 3 months, with a price target range of $6.00 to $3.00. This represents a potential 18505.58% upside from GRTS's last price of $0.03.

GRTS Analyst Ratings

Buy

According to 5 Wall Street analysts, Gritstone bio's rating consensus is 'Buy'. The analyst rating breakdown for GRTS stock is 0 'Strong Buy' (0.00%), 4 'Buy' (80.00%), 1 'Hold' (20.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Gritstone bio Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Apr 02, 2024	Kaveri Pohlman	BTIG	$3.00	$1.20	150.00%	11852.19%
Apr 02, 2024	Roy Buchanan	JMP Securities	$5.00	$2.35	112.77%	19820.32%
Oct 30, 2022	Edward Tenthoff	Piper Sandler	$6.00	$2.71	121.40%	23804.38%

Row per page

Go to

The latest Gritstone bio stock forecast, released on Apr 02, 2024 by Kaveri Pohlman from BTIG, set a price target of $3.00, which represents a 150.00% increase from the stock price at the time of the forecast ($1.20), and a 11852.19% increase from GRTS last price ($0.03).

Gritstone bio Price Target by Period

	1M	3M	12M
# Anlaysts	-	-	2
Avg Price Target	-	-	$4.00
Last Closing Price	$0.03	$0.03	$0.03
Upside/Downside	-100.00%	-100.00%	15836.25%

In the current month, the average price target of Gritstone bio stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Gritstone bio's last price of $0.03. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Oct 01, 2024	H.C. Wainwright	Underperform	Underperform	Hold
Oct 01, 2024	JMP Securities	Market Outperform	Market Outperform	Hold
Oct 01, 2024	JMP Securities	Market Perform	Perform	Downgrade
Oct 01, 2024	B. Riley	Buy	Neutral	Downgrade
Oct 01, 2024	H.C. Wainwright	Underperform	Neutral	Downgrade
Oct 01, 2024	JMP Securities	Market Outperform	Market Perform	Downgrade
Aug 14, 2024	Cowen & Co.	Buy	Buy	Hold
Aug 14, 2024	Piper Sandler	Overweight	Overweight	Hold
Aug 05, 2024	H.C. Wainwright	Underperform	Underperform	Hold
Aug 05, 2024	JMP Securities	Market Outperform	Market Outperform	Hold

Row per page

Go to

Gritstone bio's last stock rating was published by H.C. Wainwright on Oct 01, 2024. The company gave GRTS a "Underperform" rating, the same as its previous rate.

Gritstone bio Financial Forecast

Gritstone bio Revenue Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Sep 18
Revenue	-	-	-	-	-	-	-	-	$13.84M	-	$1.96M	$542.00K	$1.33M	$436.00K	$2.76M	$4.75M	$3.06M	$2.61M	$2.84M	$39.69M	$1.35M	$939.00K	$488.00K	$1.26M	$884.00K	$984.00K	$1.15M	$1.35M	$96.00K
Avg Forecast	$1.80M	$1.80M	$1.70M	$1.70M	$4.73M	$1.87M	$1.72M	$2.85M	$5.11M	$1.89M	$2.51M	$3.17M	$2.91M	$3.61M	$3.19M	$4.21M	$2.86M	$2.24M	$2.24M	$12.21M	$1.23M	$1.19M	$1.53M	$1.25M	$1.10M	$1.13M	$1.10M	$798.50K	$869.49K
High Forecast	$1.80M	$1.80M	$1.70M	$1.70M	$4.73M	$1.87M	$1.81M	$2.85M	$11.17M	$1.89M	$2.51M	$3.17M	$2.91M	$3.61M	$3.19M	$4.21M	$2.86M	$2.24M	$2.24M	$12.21M	$1.23M	$1.19M	$1.53M	$1.25M	$1.10M	$1.13M	$1.10M	$798.50K	$1.04M
Low Forecast	$1.80M	$1.80M	$1.70M	$1.70M	$4.73M	$1.87M	$1.63M	$2.85M	$1.28M	$1.89M	$2.51M	$3.17M	$2.91M	$3.61M	$3.19M	$4.21M	$2.86M	$2.24M	$2.24M	$12.21M	$1.23M	$1.19M	$1.53M	$1.25M	$1.10M	$1.13M	$1.10M	$798.50K	$695.59K
# Analysts	1	1	1	1	1	2	1	4	5	4	4	4	3	3	3	3	4	4	4	6	9	9	9	9	5	5	5	5	12
Surprise %	-	-	-	-	-	-	-	-	2.71%	-	0.78%	0.17%	0.46%	0.12%	0.86%	1.13%	1.07%	1.17%	1.27%	3.25%	1.10%	0.79%	0.32%	1.01%	0.80%	0.87%	1.05%	1.69%	0.11%

Gritstone bio's average Quarter revenue forecast for Mar 24 based on 4 analysts is $2.85M, with a low forecast of $2.85M, and a high forecast of $2.85M. GRTS's average Quarter revenue forecast represents a -79.38% decrease compared to the company's last Quarter revenue of $13.84M (Dec 23).

Gritstone bio EBITDA Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Sep 18
# Analysts	1	1	1	1	1	2	1	4	5	4	4	4	3	3	3	3	4	4	4	6	9	9	9	9	5	5	5	5	12
EBITDA	-	-	-	-	-	-	-	-	$-40.24M	-	$-35.73M	$-33.14M	$-28.82M	$-27.74M	$-28.16M	$-27.37M	$-28.20M	$-26.53M	$-23.52M	$9.52M	$-25.47M	$-24.40M	$-24.22M	$-24.58M	$-26.26M	$-26.38M	$-20.08M	$-16.97M	$-17.59M
Avg Forecast	$-1.80M	$-1.80M	$-1.70M	$-1.70M	$-4.73M	$-1.87M	$-1.72M	$-2.85M	$-5.11M	$-1.89M	$-2.51M	$-3.17M	$-2.91M	$-3.61M	$-3.19M	$-29.49M	$-2.86M	$-2.24M	$-2.24M	$-12.21M	$-1.23M	$-1.19M	$-1.53M	$-25.25M	$-1.10M	$-1.13M	$-1.10M	$-17.76M	$-159.27M
High Forecast	$-1.80M	$-1.80M	$-1.70M	$-1.70M	$-4.73M	$-1.87M	$-1.63M	$-2.85M	$-1.28M	$-1.89M	$-2.51M	$-3.17M	$-2.91M	$-3.61M	$-3.19M	$-23.59M	$-2.86M	$-2.24M	$-2.24M	$-12.21M	$-1.23M	$-1.19M	$-1.53M	$-20.20M	$-1.10M	$-1.13M	$-1.10M	$-14.21M	$-127.42M
Low Forecast	$-1.80M	$-1.80M	$-1.70M	$-1.70M	$-4.73M	$-1.87M	$-1.81M	$-2.85M	$-11.17M	$-1.89M	$-2.51M	$-3.17M	$-2.91M	$-3.61M	$-3.19M	$-35.39M	$-2.86M	$-2.24M	$-2.24M	$-12.21M	$-1.23M	$-1.19M	$-1.53M	$-30.30M	$-1.10M	$-1.13M	$-1.10M	$-21.31M	$-191.12M
Surprise %	-	-	-	-	-	-	-	-	7.88%	-	14.21%	10.46%	9.90%	7.69%	8.82%	0.93%	9.85%	11.86%	10.51%	-0.78%	20.80%	20.55%	15.82%	0.97%	23.87%	23.27%	18.25%	0.96%	0.11%

4 analysts predict GRTS's average Quarter EBITDA for Jun 21 to be $-2.24M, with a high of $-2.24M and a low of $-2.24M. This is -123.51% lower than Gritstone bio's previous annual EBITDA (Mar 21) of $9.52M.

Gritstone bio Net Income Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Sep 18
# Analysts	1	1	1	1	1	2	1	4	5	4	4	4	3	3	3	3	4	4	4	6	9	9	9	9	5	5	5	5	12
Net Income	-	-	-	-	-	-	-	-	$-30.81M	-	$-35.26M	$-33.99M	$-30.66M	$-30.05M	$-29.21M	$-28.82M	$-29.77M	$-28.12M	$-25.12M	$7.92M	$-27.17M	$-26.07M	$-25.87M	$-26.21M	$-27.70M	$-27.55M	$-21.17M	$-18.01M	$-18.59M
Avg Forecast	$-30.09M	$-27.23M	$-25.79M	$-25.79M	$-20.06M	$-24.36M	$-39.30M	$-45.68M	$-46.88M	$-48.78M	$-49.68M	$-49.50M	$-49.29M	$-57.03M	$-56.68M	$-31.26M	$-54.84M	$-74.51M	$-82.92M	$16.09M	$-87.89M	$-92.00M	$-102.70M	$-26.92M	$-102.15M	$-94.75M	$-88.49M	$-18.84M	$-168.35M
High Forecast	$-30.09M	$-27.23M	$-25.79M	$-25.79M	$-20.06M	$-24.36M	$-39.30M	$-45.68M	$-41.67M	$-48.78M	$-49.68M	$-49.50M	$-49.29M	$-57.03M	$-56.68M	$-25.01M	$-54.84M	$-74.51M	$-82.92M	$19.31M	$-87.89M	$-92.00M	$-102.70M	$-21.54M	$-102.15M	$-94.75M	$-88.49M	$-15.07M	$-134.68M
Low Forecast	$-30.09M	$-27.23M	$-25.79M	$-25.79M	$-20.06M	$-24.36M	$-39.30M	$-45.68M	$-54.69M	$-48.78M	$-49.68M	$-49.50M	$-49.29M	$-57.03M	$-56.68M	$-37.51M	$-54.84M	$-74.51M	$-82.92M	$12.87M	$-87.89M	$-92.00M	$-102.70M	$-32.31M	$-102.15M	$-94.75M	$-88.49M	$-22.61M	$-202.03M
Surprise %	-	-	-	-	-	-	-	-	0.66%	-	0.71%	0.69%	0.62%	0.53%	0.52%	0.92%	0.54%	0.38%	0.30%	0.49%	0.31%	0.28%	0.25%	0.97%	0.27%	0.29%	0.24%	0.96%	0.11%

Gritstone bio's average Quarter net income forecast for Jun 21 is $-82.92M, with a range of $-82.92M to $-82.92M. GRTS's average Quarter net income forecast represents a -1146.61% decrease compared to the company's last Quarter net income of $7.92M (Mar 21).

Gritstone bio SG&A Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Sep 18
# Analysts	1	1	1	1	1	2	1	4	5	4	4	4	3	3	3	3	4	4	4	6	9	9	9	9	5	5	5	5	12
SG&A	-	-	-	-	-	-	-	-	$7.92M	-	$6.72M	$6.75M	$6.76M	$6.46M	$7.79M	$7.96M	$6.68M	$6.37M	$5.94M	$6.94M	$5.66M	$5.03M	$5.25M	$5.46M	$5.62M	$4.58M	$4.83M	$4.38M	$3.09M
Avg Forecast	$10.57M	$10.57M	$9.98M	$9.98M	$27.79M	$10.96M	$10.10M	$16.75M	$29.99M	$11.12M	$14.76M	$18.59M	$17.08M	$21.18M	$18.74M	$24.73M	$16.80M	$13.14M	$13.14M	$71.69M	$7.19M	$6.97M	$8.99M	$7.36M	$6.46M	$6.65M	$6.46M	$4.69M	$5.10M
High Forecast	$10.57M	$10.57M	$9.98M	$9.98M	$27.79M	$10.96M	$10.61M	$16.75M	$65.60M	$11.12M	$14.76M	$18.59M	$17.08M	$21.18M	$18.74M	$24.73M	$16.80M	$13.14M	$13.14M	$71.69M	$7.19M	$6.97M	$8.99M	$7.36M	$6.46M	$6.65M	$6.46M	$4.69M	$6.13M
Low Forecast	$10.57M	$10.57M	$9.98M	$9.98M	$27.79M	$10.96M	$9.58M	$16.75M	$7.50M	$11.11M	$14.76M	$18.59M	$17.08M	$21.18M	$18.74M	$24.73M	$16.80M	$13.14M	$13.14M	$71.69M	$7.19M	$6.97M	$8.99M	$7.36M	$6.46M	$6.65M	$6.46M	$4.69M	$4.08M
Surprise %	-	-	-	-	-	-	-	-	0.26%	-	0.46%	0.36%	0.40%	0.31%	0.42%	0.32%	0.40%	0.49%	0.45%	0.10%	0.79%	0.72%	0.58%	0.74%	0.87%	0.69%	0.75%	0.93%	0.60%

Gritstone bio's average Quarter SG&A projection for Mar 24 is $16.75M, based on 4 Wall Street analysts, with a range of $16.75M to $16.75M. The forecast indicates a 111.63% rise compared to GRTS last annual SG&A of $7.92M (Dec 23).

Gritstone bio EPS Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Sep 18
# Analysts	1	1	1	1	1	2	1	4	5	4	4	4	3	3	3	3	4	4	4	6	9	9	9	9	5	5	5	5	12
EPS	-	-	-	-	-	-	-	-	$-0.00	-	$-0.00	$-0.30	$-0.34	$-0.35	$-0.34	$-0.33	$-0.38	$-0.36	$-0.33	$0.10	$-0.72	$-0.69	$-0.69	$-0.71	$-0.75	$-0.77	$-0.63	$-0.62	$-7.60
Avg Forecast	$-0.21	$-0.19	$-0.18	$-0.18	$-0.14	$-0.17	$-0.27	$-0.32	$-0.33	$-0.34	$-0.35	$-0.35	$-0.34	$-0.40	$-0.40	$-0.37	$-0.38	$-0.52	$-0.58	$-0.39	$-0.61	$-0.64	$-0.72	$-0.73	$-0.71	$-0.66	$-0.62	$-0.65	$-5.71
High Forecast	$-0.21	$-0.19	$-0.18	$-0.18	$-0.14	$-0.17	$-0.27	$-0.32	$-0.29	$-0.34	$-0.35	$-0.35	$-0.34	$-0.40	$-0.40	$-0.37	$-0.38	$-0.52	$-0.58	$-0.39	$-0.61	$-0.64	$-0.72	$-0.73	$-0.71	$-0.66	$-0.62	$-0.65	$-4.56
Low Forecast	$-0.21	$-0.19	$-0.18	$-0.18	$-0.14	$-0.17	$-0.27	$-0.32	$-0.38	$-0.34	$-0.35	$-0.35	$-0.34	$-0.40	$-0.40	$-0.37	$-0.38	$-0.52	$-0.58	$-0.39	$-0.61	$-0.64	$-0.72	$-0.73	$-0.71	$-0.66	$-0.62	$-0.65	$-6.85
Surprise %	-	-	-	-	-	-	-	-	0.00%	-	0.00%	0.87%	0.99%	0.88%	0.86%	0.90%	0.99%	0.69%	0.57%	-0.26%	1.17%	1.07%	0.96%	0.97%	1.06%	1.16%	1.02%	0.95%	1.33%

According to 4 Wall Street analysts, Gritstone bio's projected average Quarter EPS for Jun 21 is $-0.58, with a low estimate of $-0.58 and a high estimate of $-0.58. This represents a -678.68% decrease compared to GRTS previous annual EPS of $0.10 (Mar 21).

Gritstone bio Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
GRTS	Gritstone bio	$0.03	$4.67	15466.67%	Buy
ALLO	Allogene Therapeutics	$2.11	$29.00	1274.41%	Buy
PASG	Passage Bio	$0.54	$6.00	1011.11%	Buy
HRTX	Heron Therapeutics	$1.06	$7.00	560.38%	Buy
SGMO	Sangamo Therapeutics	$1.96	$12.00	512.24%	Buy
ADAP	Adaptimmune Therapeutics	$0.64	$2.83	342.19%	Buy
ANVS	Annovis Bio	$6.79	$25.67	278.06%	Buy
CCCC	C4 Therapeutics	$4.01	$13.50	236.66%	Buy
FULC	Fulcrum Therapeutics	$2.97	$9.86	231.99%	Buy
IFRX	InflaRx	$2.06	$6.00	191.26%	Strong Buy
AFMD	Affimed	$2.64	$7.50	184.09%	Buy
ANNX	Annexon	$5.17	$14.00	170.79%	Buy
ERAS	Erasca	$2.60	$6.50	150.00%	Buy
KZR	Kezar Life Sciences	$7.62	$17.50	129.66%	Buy
LPTX	Leap Therapeutics	$2.58	$5.50	113.18%	Buy
BBIO	BridgeBio Pharma	$23.24	$45.00	93.63%	Buy
KRON	Kronos Bio	$0.87	$1.63	87.36%	Buy
EWTX	Edgewise Therapeutics	$31.98	$45.00	40.71%	Buy
AUPH	Aurinia Pharmaceuticals	$8.77	$10.75	22.58%	Buy
CRVS	Corvus Pharmaceuticals	$8.94	$10.67	19.35%	Buy
GTHX	G1 Therapeutics	$7.16	$4.50	-37.15%	Buy

GRTS Forecast FAQ

Is Gritstone bio a good buy?

Yes, according to 5 Wall Street analysts, Gritstone bio (GRTS) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 4 'Buy' recommendations, accounting for 80.00% of GRTS's total ratings.

What is GRTS's price target?

Gritstone bio (GRTS) average price target is $4.67 with a range of $3 to $6, implying a 18505.58% from its last price of $0.0251. The data is based on 5 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Gritstone bio stock go up soon?

According to Wall Street analysts' prediction for GRTS stock, the company can go up by 18505.58% (from the last price of $0.0251 to the average price target of $4.67), up by 23804.38% based on the highest stock price target, and up by 11852.19% based on the lowest stock price target.

Can Gritstone bio stock reach $0?

GRTS's average twelve months analyst stock price target of $4.67 supports the claim that Gritstone bio can reach $0 in the near future.

What are Gritstone bio's analysts' financial forecasts?

Gritstone bio's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $11.17M (high $11.26M, low $11.09M), average EBITDA is $-11.174M (high $-11.086M, low $-11.262M), average net income is $-129M (high $-129M, low $-129M), average SG&A $65.6M (high $66.11M, low $65.08M), and average EPS is $-0.903 (high $-0.903, low $-0.903). GRTS's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $7M (high $7M, low $7M), average EBITDA is $-7M (high $-7M, low $-7M), average net income is $-109M (high $-109M, low $-109M), average SG&A $41.09M (high $41.09M, low $41.09M), and average EPS is $-0.76 (high $-0.76, low $-0.76).

Did the GRTS's actual financial results beat the analysts' financial forecasts?

Based on Gritstone bio's last annual report (Dec 2023), the company's revenue was $16.34M, beating the average analysts forecast of $12.68M by 28.87%. Apple's EBITDA was $-140M, beating the average prediction of $-12.682M by 1000.92%. The company's net income was $-138M, missing the average estimation of $-195M by -28.92%. Apple's SG&A was $28.78M, missing the average forecast of $74.45M by -61.34%. Lastly, the company's EPS was $-0.0012, missing the average prediction of $-1.36 by -99.91%. In terms of the last quarterly report (Dec 2023), Gritstone bio's revenue was $13.84M, beating the average analysts' forecast of $5.11M by 170.88%. The company's EBITDA was $-40.24M, beating the average prediction of $-5.108M by 687.76%. Gritstone bio's net income was $-30.808M, missing the average estimation of $-46.881M by -34.28%. The company's SG&A was $7.92M, missing the average forecast of $29.99M by -73.60%. Lastly, the company's EPS was $-0.0003, missing the average prediction of $-0.327 by -99.91%